Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer

OBJECTIVES:

1. To collect, catalog and store frozen samples of lung carcinoma and when possible,
portions of involved lymph nodes, as well as adjacent grossly uninvolved lung tissue
obtained from surgical specimens of patients undergoing surgical resection for
previously untreated lung cancer as a source of quality DNA, messenger ribonucleic acid
(mRNA) and protein for molecular analysis.

2. To collect, catalog and store frozen samples of blood pre- and post-resection from the
same patients to provide a source of reference DNA to assess somatic mutations
associated with tumor or preneoplastic "normal" lung, and to allow assessment of levels
of circulating markers.

3. To associate these specimens with historical, clinical, pathological, and outcome
information.

Grossly viable tumor and grossly normal lung tissue are identified and removed from patient
surgical specimens and cryopreserved until shipment to the Cancer and Leukemia Group B
(CALGB) Lung Cancer Tissue Bank for future use in research. Blood specimens are also
collected prior to surgery and at 4-12 weeks post-surgery (before the start of adjuvant
therapy) and shipped immediately to the Tissue Bank.

1. Histologic Documentation: All patients with suspected or histologically documented
previously untreated lung cancer undergoing surgical resection are eligible whether or
not the patient participates in a CALGB-sponsored treatment trial; patients enrolled
on a CALGB trial of preoperative chemotherapy for lung cancer will be eligible if a
pre-treatment frozen sample of tumor (e.g., a positive lymph node from
mediastinoscopy) can be submitted to the bank; patients enrolled on CALGB 140203,
intraoperative sentinel node mapping in non-small cell lung cancer, are not eligible.

2. No patients with known infectious disease, such as human immunodeficiency virus (HIV),
tuberculosis (TB), or hepatitis B, C